Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Germany: Activation of bitter taste receptors opens lung pathways, making them potential targets for the treatment of chronic lung diseases...
Read Full NewsImproving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches
Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer
Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer
Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer
Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer
Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly
Navigating Advances in Cystic Fibrosis Care
1.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
2.
The FDA approves Enhertu for HER2-positive cancers, regardless of tumor type.
3.
'Personalized' Approach to RT for Bladder Cancer Promising but Challenging
4.
Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?
5.
Obesity-associated cancers tripled nationwide over past two decades
1.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
2.
Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights
3.
Deep Learning Fluorescence Imaging for Oral Cancer Surgery: In Silico Depth Quantification
4.
Polycythemia Vera: A Historical Perspective and Contemporary Management
5.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Navigating the Complexities of Ph Negative ALL - Part IX
2.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
3.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
5.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge